Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery

Sarcoglycanopathies are rare limb girdle muscular dystrophies, still incurable, even though symptomatic treatments may slow down the disease progression. Most of the disease-causing defects are missense mutations leading to a folding defective protein, promptly removed by the cell’s qualit...

Full description

Bibliographic Details
Main Authors: Marcello Carotti, Martina Scano, Irene Fancello, Isabelle Richard, Giovanni Risato, Mona Bensalah, Michela Soardi, Dorianna Sandonà
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/5/1813
id doaj-1296b28e0b70450795dd8904e3328517
record_format Article
spelling doaj-1296b28e0b70450795dd8904e33285172020-11-25T03:00:20ZengMDPI AGInternational Journal of Molecular Sciences1422-00672020-03-01215181310.3390/ijms21051813ijms21051813Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex RecoveryMarcello Carotti0Martina Scano1Irene Fancello2Isabelle Richard3Giovanni Risato4Mona Bensalah5Michela Soardi6Dorianna Sandonà7Department of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, ItalyDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, ItalyDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, ItalyGénéthon INSERM, U951, INTEGRARE Research Unit, Univ Evry, Université Paris-Saclay, 91002 Evry, FranceDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, ItalyINSERM, Institut de Myologie, U974, Center for Research in Myology, Sorbonne Université, 75013 Paris, FranceDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, ItalyDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/b 35131 Padova, ItalySarcoglycanopathies are rare limb girdle muscular dystrophies, still incurable, even though symptomatic treatments may slow down the disease progression. Most of the disease-causing defects are missense mutations leading to a folding defective protein, promptly removed by the cell’s quality control, even if possibly functional. Recently, we repurposed small molecules screened for cystic fibrosis as potential therapeutics in sarcoglycanopathy. Indeed, cystic fibrosis transmembrane regulator (CFTR) correctors successfully recovered the defective sarcoglycan-complex in vitro. Our aim was to test the combined administration of some CFTR correctors with C17, the most effective on sarcoglycans identified so far, and evaluate the stability of the rescued sarcoglycan-complex. We treated differentiated myogenic cells from both sarcoglycanopathy and healthy donors, evaluating the global rescue and the sarcolemma localization of the mutated protein, by biotinylation assays and western blot analyses. We observed the additive/synergistic action of some compounds, gathering the first ideas on possible mechanism/s of action. Our data also suggest that a defective α-sarcoglycan is competent for assembly into the complex that, if helped in cell traffic, can successfully reach the sarcolemma. In conclusion, our results strengthen the idea that CFTR correctors, acting probably as proteostasis modulators, have the potential to progress as therapeutics for sarcoglycanopathies caused by missense mutations.https://www.mdpi.com/1422-0067/21/5/1813sarcoglycanopathymyogenic cellsmyotubesfolding-defective proteinsprotein folding correctorscftr correctorsproteostasis regulators
collection DOAJ
language English
format Article
sources DOAJ
author Marcello Carotti
Martina Scano
Irene Fancello
Isabelle Richard
Giovanni Risato
Mona Bensalah
Michela Soardi
Dorianna Sandonà
spellingShingle Marcello Carotti
Martina Scano
Irene Fancello
Isabelle Richard
Giovanni Risato
Mona Bensalah
Michela Soardi
Dorianna Sandonà
Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
International Journal of Molecular Sciences
sarcoglycanopathy
myogenic cells
myotubes
folding-defective proteins
protein folding correctors
cftr correctors
proteostasis regulators
author_facet Marcello Carotti
Martina Scano
Irene Fancello
Isabelle Richard
Giovanni Risato
Mona Bensalah
Michela Soardi
Dorianna Sandonà
author_sort Marcello Carotti
title Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
title_short Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
title_full Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
title_fullStr Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
title_full_unstemmed Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
title_sort combined use of cftr correctors in lgmd2d myotubes improves sarcoglycan complex recovery
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2020-03-01
description Sarcoglycanopathies are rare limb girdle muscular dystrophies, still incurable, even though symptomatic treatments may slow down the disease progression. Most of the disease-causing defects are missense mutations leading to a folding defective protein, promptly removed by the cell’s quality control, even if possibly functional. Recently, we repurposed small molecules screened for cystic fibrosis as potential therapeutics in sarcoglycanopathy. Indeed, cystic fibrosis transmembrane regulator (CFTR) correctors successfully recovered the defective sarcoglycan-complex in vitro. Our aim was to test the combined administration of some CFTR correctors with C17, the most effective on sarcoglycans identified so far, and evaluate the stability of the rescued sarcoglycan-complex. We treated differentiated myogenic cells from both sarcoglycanopathy and healthy donors, evaluating the global rescue and the sarcolemma localization of the mutated protein, by biotinylation assays and western blot analyses. We observed the additive/synergistic action of some compounds, gathering the first ideas on possible mechanism/s of action. Our data also suggest that a defective α-sarcoglycan is competent for assembly into the complex that, if helped in cell traffic, can successfully reach the sarcolemma. In conclusion, our results strengthen the idea that CFTR correctors, acting probably as proteostasis modulators, have the potential to progress as therapeutics for sarcoglycanopathies caused by missense mutations.
topic sarcoglycanopathy
myogenic cells
myotubes
folding-defective proteins
protein folding correctors
cftr correctors
proteostasis regulators
url https://www.mdpi.com/1422-0067/21/5/1813
work_keys_str_mv AT marcellocarotti combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT martinascano combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT irenefancello combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT isabellerichard combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT giovannirisato combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT monabensalah combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT michelasoardi combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
AT doriannasandona combineduseofcftrcorrectorsinlgmd2dmyotubesimprovessarcoglycancomplexrecovery
_version_ 1724698693543657472